Loading data for LEXX — first visit, this takes a few seconds.
Lexaria Bioscience Corp. (LEXX)
: LEXX
· Real-Time Price · USD
n/a
n/a (n/a)
At close: Invalid Date
11.42
-2.23%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Lexaria Bioscience Corp. (LEXX) Stock Price, Analysis & Data
No data available
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | 194K |
| Net Income (ttm) | -7.73M |
| 0.37 | |
| n/a | |
| n/a | |
| -29.95 | |
| P/B (ttm) | 4.07 |
| P/S (ttm) | 99.49 |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | NaN |
| Avg. Volume (20D) | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a - n/a |
| 52-Week Range | n/a - n/a |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting he...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 12, 2021
Employees 7
Stock Exchange NasdaqCM
Ticker Symbol LEXX
Website https://lexariabioscience.com
Financial Performance
In 2025, Lexaria Bioscience's revenue was 705.92K, an increase of 52.05% compared to the previous year's 464.28K. Earnings were -11.9M, an increase of 105.37%.
Financial Statements